Analysis of the Adjuvant Therapeutic Effect of Epalrestat Tablets in Enhancing the Treatment of Diabetic Complications

Objective: To evaluate the adjuvant therapeutic effect of Epalrestat tablets on diabetic complications. Methods: 96 patients with diabetic complications who were admitted to the hospital from September 2021 to September 2023 were selected and randomly divided into two groups using a random number table. The observation group was treated with Epalrestat tablets combined with Ginkgo Dipyridolum Injection, while the control group was treated with Ginkgo Dipyridolum Injection only. The total effective rate, blood glucose indicators, oxidative stress indicators, and adverse reaction rates were compared between the two groups. Results: The total effective rates of diabetic nephropathy (DN), diabetic foot (DF), and diabetic peripheral neuropathy (DPN) in the observation group were higher than those in the control group (P < 0.05). After 12 weeks of treatment, the blood glucose indicators in the observation group were lower than those in the control group, and the oxidative stress indicators were better than those in the control group (P < 0.05). The adverse reaction rate in the observation group was lower than that in the control group (P < 0.05). Conclusion: Epalrestat tablets can assist in improving the clinical efficacy of patients with diabetic complications, lowering their blood glucose levels, reducing oxidative stress damage, and decreasing adverse reactions after medication.